Loading
Latest filing published 06 Aug 2026 for Prostatype Genomics AB, €200k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Håkan Englund (board member) discloses dealings in Prostatype Genomics AB to Finansinspektionen. We count 2 filings; the first trade dates from 4 June 2025 and the latest from 29 July 2026.
The open-market record is one-sided, with 2 purchases worth €264k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2026: 1 purchase and no sales on the market.
On 6 August 2026 came the latest disclosure, an open-market purchase for €200k in Prostatype Genomics AB. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations